ClinicalTrials.gg
Not yet recruitingNCT07862491CANMOVEUpdated Oct 7, 2026

Physical Activity and Functional Capacity in Patients With Congenital Long QT Syndrome

An observational study in Long QT Syndrome and Channelopathies, sponsored by University of Sao Paulo. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Sao Paulo · Observational

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

Patients with congenital long QT syndrome (LQTS) have traditionally been discouraged from physical activity and competitive sports, although the rate of exercise-related arrhythmic events is considered low. In recent years, international guidelines have become less restrictive and now support shared decision-making between physicians, patients and families to promote safe physical activity. Excessive restriction, especially in young people, may negatively affect mental health, quality of life and overall cardiovascular risk. However, little is known about the physical activity level and physical fitness of patients with LQTS in clinical practice.

This observational study will describe the baseline functional capacity, physical activity level and quality of life of adults with congenital LQTS followed at the Arrhythmia Outpatient Clinic of the Heart Institute (InCor), São Paulo, Brazil, and compare them with patients with arrhythmias and a structurally normal heart. Participants will answer questionnaires on physical activity, quality of life and barriers to exercise, and will undergo cardiopulmonary exercise testing and 24-hour Holter monitoring. This is the first step of the Channelopathies Movement and Exercise Study (CANMOVE).

Read the detailed description

Background

Congenital long QT syndrome (LQTS) is a genetically determined channelopathy characterized by delayed ventricular repolarization, which may cause syncope, ventricular arrhythmias and sudden cardiac death. The three most frequent subtypes, associated with variants in KCNQ1 (LQT1), KCNH2 (LQT2) and SCN5A (LQT3), account for about 90% of genotype-positive cases and have specific arrhythmic triggers: exercise in LQT1, auditory stimuli in LQT2 and rest in LQT3.

Patients with LQTS have historically been advised against most sports. Recent American and European recommendations are less restrictive and favor shared decision-making, especially in asymptomatic genotype-positive, phenotype-negative individuals. Registry data suggest a low rate of sport-related events in athletes with LQTS who remain active under appropriate management, including beta-blocker therapy. On the other hand, children with LQTS have shown lower peak oxygen consumption and ventilatory anaerobic threshold than healthy controls, possibly due to beta-blocker-induced chronotropic limitation and deconditioning. There are no data on the physical activity profile and functional capacity of patients with LQTS followed in Brazilian clinical practice.

The Channelopathies Movement and Exercise Study (CANMOVE) is a broader initiative to analyze physical activity in patients with cardiac channelopathies. This project is its first step, focused on congenital LQTS.

Study design

Single-center observational study at the Heart Institute (Instituto do Coração, InCor), Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Brazil. The study combines a historical cohort, with physical activity data partially obtained from a previously approved study on physical activity in patients with cardiac arrhythmias (SDC 5310/21/085), and prospective inclusion of new patients with LQTS during the study period. The control group will consist of patients with cardiac arrhythmias and a structurally normal heart already included in the previous study, selected by propensity score matching.

Procedures

  1. Questionnaires: the International Physical Activity Questionnaire short form (IPAQ), validated for the Brazilian population; the 12-Item Short Form Health Survey (SF-12) for quality of life; and a structured questionnaire on daily life after diagnosis of arrhythmia or device implantation, including reasons for not exercising and the desire to engage in physical exercise. Questionnaires will be applied before the outpatient visit.
  2. Resting 12-lead electrocardiogram (ECG): heart rate, baseline corrected QT interval (QTc) by Bazett's formula and presence of T-wave notching in at least three contiguous leads. Diagnosis of LQTS will follow the criteria of the 2022 European Society of Cardiology (ESC) guidelines for ventricular arrhythmias and prevention of sudden cardiac death.
  3. Cardiopulmonary exercise testing (CPET): treadmill ramp protocol with continuous metabolic, ventilatory and 12-lead ECG monitoring until exhaustion. Variables include peak oxygen consumption (VO2 peak), ventilatory anaerobic threshold, respiratory compensation point, heart rate and blood pressure responses, and QTc at rest (supine and standing, with orthostatic provocation), at peak exercise and during recovery.
  4. 24-hour Holter monitoring: continuous 3-channel ECG recording for arrhythmia detection and heart rate variability (HRV) analysis.
  5. Genetic testing: next-generation sequencing (NGS) panel including genes associated with LQTS, with variant classification according to the American College of Medical Genetics and Genomics (ACMG) criteria and discussion by a multidisciplinary group. Genetic data will be obtained from the clinical database of the Arrhythmia Unit.

All prospective participants will undergo CPET and 24-hour Holter monitoring using a standardized protocol for patients with LQTS. Beta-blocker therapy and other treatments (antiarrhythmic drugs, implantable cardioverter-defibrillator [ICD], sympathectomy) will be recorded. Data will be collected from electronic medical records and stored in the Research Electronic Data Capture (REDCap) platform.

Statistical analysis

Approximately 60 patients with congenital LQTS are expected. Categorical variables will be presented as absolute and relative frequencies, and continuous variables as mean and standard deviation or median and interquartile range. Patients with LQTS will be compared with controls matched by propensity score, calculated by logistic regression. Associations between categorical variables will be assessed by chi-square or Fisher's exact test, and continuous variables will be compared by Student's t test or Mann-Whitney test, according to distribution. P values below 0.05 will be considered statistically significant.

02

Conditions studied

  • Long QT Syndrome
  • Channelopathies

Keywords

  • Congenital long QT syndrome
  • Physical activity
03

In context

Long QT Syndrome

101 studies on the registry are indexed under Long QT Syndrome; 20 are open to participants now.

This study's planned enrollment of 120 is below the median of 150 across 53 observational studies indexed under Long QT Syndrome.

Browse Long QT Syndrome studies →

Lead sponsor

University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with congenital long QT syndrome followed at the Arrhythmia Outpatient Clinic of the Heart Institute (InCor), Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Brazil. Controls are patients with cardiac arrhythmias and a structurally normal heart from the same institution.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Confirmed diagnosis of congenital long syndrome, followed at the Arrhythmia Outpatient Clinic of the Heart Institute (InCor)
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Acquired long syndrome
  • No diagnostic confirmation by clinical and/or genetic criteria, without the possibility of genetic testing as part of routine care
  • Corrected QT interval (QTc) persistently above 500 ms
  • Any implantable cardioverter-defibrillator (ICD) therapy or unexplained syncope in the previous 6 months
  • Bedridden patients or patients with walking difficulties
  • (ECOG) performance status of 2 or higher
  • Non-adherence to drug treatment
  • Advanced-stage disease with estimated survival of less than 1 year
  • Advanced cognitive impairment or inability to answer the questionnaires
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Congenital long QT syndrome

    Adults with a confirmed diagnosis of congenital long QT syndrome (LQTS) by clinical and/or genetic criteria, followed at the Arrhythmia Outpatient Clinic of the Heart Institute (InCor).

    Other: Questionnaires · Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: 24-hour Holter monitoring

  • Group 2: Arrhythmia with structurally normal heart

    Patients with cardiac arrhythmias and a structurally normal heart from a previous study on physical activity in patients with cardiac arrhythmias, selected by propensity score matching.

    Other: Questionnaires · Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: 24-hour Holter monitoring

Interventions

  • OtherQuestionnaires

    International Physical Activity Questionnaire short form (IPAQ), 12-Item Short Form Health Survey (SF-12) and structured questionnaire on daily life and barriers to physical activity.

  • Diagnostic testCardiopulmonary exercise testing

    Treadmill ramp protocol with continuous metabolic, ventilatory and 12-lead electrocardiogram monitoring until exhaustion.

  • Diagnostic test24-hour Holter monitoring

    Continuous 3-channel electrocardiogram recording for 24 hours.

06

What researchers measure

Primary outcomes

  1. Peak oxygen consumption (VO2 peak)

    Baseline functional capacity measured as peak oxygen consumption (mL/kg/min) on cardiopulmonary exercise testing.

    Time frame: At baseline (single assessment)

Secondary outcomes

  1. Physical activity level

    Weekly time spent walking and in moderate and vigorous physical activity, measured by the International Physical Activity Questionnaire short form (IPAQ).

    Time frame: At baseline (single assessment)

  2. Quality of life Questionnaire

    Physical and mental component scores of the 12-Item Short Form Health Survey (SF-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: At baseline

  3. Proportion of patients who wish to engage in physical exercise

    Proportion of participants answering yes to the question on willingness to practice physical exercise in the structured daily life questionnaire.

    Time frame: At baseline

  4. Reasons for not practicing physical exercise

    Frequency of each reported reason for not exercising (medical advice, dislike, lack of time, arrhythmia diagnosis, defibrillator shock, device implantation) in the structured daily life questionnaire.

    Time frame: At baseline

  5. Association between physical activity level and arrhythmias

    Association between physical activity level measured by the International Physical Activity Questionnaire (IPAQ) and the type and frequency of arrhythmias detected on 24-hour Holter monitoring and cardiopulmonary exercise testing.

    Time frame: At baseline

  6. Heart rate variability

    Time-domain heart rate variability indices measured on 24-hour Holter monitoring.

    Time frame: At baseline

  7. Corrected QT interval during exercise and recovery

    Corrected QT interval (QTc, ms) at rest (supine and standing), at peak exercise and during recovery on cardiopulmonary exercise testing.

    Time frame: At baseline

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 21 observational studies under Long QT Syndrome, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 81. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartEst.
Nov 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07862491
Responsible party
Savia Christina Pereira Bueno (Principal Investigator, University of Sao Paulo) — Principal investigator
First posted
Oct 7, 2026
Start date
Nov 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Savia Bueno, MD, PhD
Contact
savia_bueno@hotmail.com
+55 11 2661-5341

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion